Old Web
English
Sign In
Acemap
>
authorDetail
>
Kate Nicholson
Kate Nicholson
Newbury College
Placebo
Doxorubicin
Hepatocellular carcinoma
Clinical endpoint
Sorafenib
2
Papers
500
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
2016
Journal of Hepatology
Riccardo Lencioni
Josep M. Llovet
Guohong Han
Won Young Tak
Jiamei Yang
Alfredo Guglielmi
Seung Woon Paik
María Reig
Do Young Kim
Gar-Yang Chau
Angelo Luca
Luis Ruiz-del-Arbol
Marie-Aude Leberre
Woody Niu
Kate Nicholson
Gerold Meinhardt
Jordi Bruix
Show All
Source
Cite
Save
Citations (365)
Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
2012
Journal of Clinical Oncology
Riccardo Lencioni
Josep M. Llovet
Guohong Han
Won Young Tak
Jiamei Yang
Marie-Aude Leberre
Woody Niu
Kate Nicholson
Gerold Meinhardt
Jordi Bruix
Show All
Source
Cite
Save
Citations (135)
1